Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25757
Abstract: Urelumab, a fully human, non‐ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T‐cell and natural killer‐cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. Here we report results in patients with… read more here.
Keywords: relapsed refractory; combination; patients relapsed; cell ... See more keywords